108 related articles for article (PubMed ID: 18508156)
1. Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins.
Akizawa H; Uehara T; Arano Y
Adv Drug Deliv Rev; 2008 Sep; 60(12):1319-28. PubMed ID: 18508156
[TBL] [Abstract][Full Text] [Related]
2. Strategies to reduce renal radioactivity levels of antibody fragments.
Arano Y
Q J Nucl Med; 1998 Dec; 42(4):262-70. PubMed ID: 9973841
[TBL] [Abstract][Full Text] [Related]
3. In vitro system to estimate renal brush border enzyme-mediated cleavage of Peptide linkages for designing radiolabeled antibody fragments of low renal radioactivity levels.
Fujioka Y; Satake S; Uehara T; Mukai T; Akizawa H; Ogawa K; Saji H; Endo K; Arano Y
Bioconjug Chem; 2005; 16(6):1610-6. PubMed ID: 16287261
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and evaluation of [188Re]organorhenium-labeled antibody fragments with renal enzyme-cleavable linkage for low renal radioactivity levels.
Uehara T; Koike M; Nakata H; Hanaoka H; Iida Y; Hashimoto K; Akizawa H; Endo K; Arano Y
Bioconjug Chem; 2007; 18(1):190-8. PubMed ID: 17226973
[TBL] [Abstract][Full Text] [Related]
5. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention.
Vegt E; de Jong M; Wetzels JF; Masereeuw R; Melis M; Oyen WJ; Gotthardt M; Boerman OC
J Nucl Med; 2010 Jul; 51(7):1049-58. PubMed ID: 20554737
[TBL] [Abstract][Full Text] [Related]
6. Renal handling of proteins and peptides.
Carone FA
Ann Clin Lab Sci; 1978; 8(4):287-94. PubMed ID: 686646
[TBL] [Abstract][Full Text] [Related]
7. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations.
Behr TM; Goldenberg DM; Becker W
Eur J Nucl Med; 1998 Feb; 25(2):201-12. PubMed ID: 9473271
[TBL] [Abstract][Full Text] [Related]
8. Preferential Cleavage of a Tripeptide Linkage by Enzymes on Renal Brush Border Membrane To Reduce Renal Radioactivity Levels of Radiolabeled Antibody Fragments.
Suzuki C; Uehara T; Kanazawa N; Wada S; Suzuki H; Arano Y
J Med Chem; 2018 Jun; 61(12):5257-5268. PubMed ID: 29869881
[TBL] [Abstract][Full Text] [Related]
9. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
[TBL] [Abstract][Full Text] [Related]
10. Renal brush border strategy: A developing procedure to reduce renal radioactivity levels of radiolabeled polypeptides.
Arano Y
Nucl Med Biol; 2021 Jan; 92():149-155. PubMed ID: 32169305
[TBL] [Abstract][Full Text] [Related]
11. [Design of radiolabeled antibody fragments for tumor-selective radioactivity localization--brush border enzyme-sensitive bond to decrease renal accumulation of radioactivity].
Mukai T; Fujioka Y; Arano Y; Saji H
Yakugaku Zasshi; 2003 Aug; 123(8):647-52. PubMed ID: 12931660
[TBL] [Abstract][Full Text] [Related]
12. Dual MVK cleavable linkers effectively reduce renal retention of
Valpreda G; Trachsel B; Vogel V; Schibli R; Mu L; Behe M
Bioorg Med Chem; 2022 Nov; 73():117040. PubMed ID: 36202066
[TBL] [Abstract][Full Text] [Related]
13. Altering pharmacokinetics of radiolabeled antibodies by the interposition of metabolizable linkages. Metabolizable linkers and pharmacokinetics of monoclonal antibodies.
Akizawa H; Arano Y
Q J Nucl Med; 2002 Sep; 46(3):206-23. PubMed ID: 12134137
[TBL] [Abstract][Full Text] [Related]
14. Proceedings: The bovine protease inhibitor as a tool for studying the renal reabsorption of peptides.
Just M; Habermann E
Naunyn Schmiedebergs Arch Pharmacol; 1974; 282(Suppl):suppl 282:R43. PubMed ID: 4276578
[No Abstract] [Full Text] [Related]
15. Cleavable linkers to enhance selectivity of antibody-targeted therapy of cancer.
Kukis DL; Novak-Hofer I; DeNardo SJ
Cancer Biother Radiopharm; 2001 Dec; 16(6):457-67. PubMed ID: 11789023
[TBL] [Abstract][Full Text] [Related]
16. Receptor-mediated tumor targeting with radiopeptides. Part 1. General principles and methods.
Eberle AN; Mild G
J Recept Signal Transduct Res; 2009; 29(1):1-37. PubMed ID: 19519167
[TBL] [Abstract][Full Text] [Related]
17. Reduction of the Renal Radioactivity of
Suzuki H; Araki M; Tatsugi K; Ichinohe K; Uehara T; Arano Y
J Med Chem; 2023 Jul; 66(13):8600-8613. PubMed ID: 37322876
[TBL] [Abstract][Full Text] [Related]
18. Hypertension-mediated albuminuria is associated with reduced lysosomal activity in the kidney and the heart.
Hilliard LM; Russo LM; Comper WD
Am J Nephrol; 2009; 29(5):454-64. PubMed ID: 19023196
[TBL] [Abstract][Full Text] [Related]
19. Specific labeling with potent radiolabels alters the uptake of cell-penetrating peptides.
Walther C; Ott I; Gust R; Neundorf I
Biopolymers; 2009; 92(5):445-51. PubMed ID: 19399852
[TBL] [Abstract][Full Text] [Related]
20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
